These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30926675)

  • 1. The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma.
    Swami U; Grivas P; Agarwal N
    Oncologist; 2019 May; 24(5):580-583. PubMed ID: 30926675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Teo MY; Rosenberg JE
    Urol Clin North Am; 2018 May; 45(2):287-295. PubMed ID: 29650143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder.
    Song Y; Xu T
    World J Urol; 2023 Jun; 41(6):1697-1698. PubMed ID: 37183202
    [No Abstract]   [Full Text] [Related]  

  • 5. New option for cisplatin-ineligible urothelial cancer.
    Dreicer R
    Lancet Oncol; 2017 Nov; 18(11):1428-1430. PubMed ID: 28967486
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma.
    Einerhand SMH; van Dorp J; van der Heijden MS; van Rhijn BWG
    Eur Urol; 2023 Jan; 83(1):91-92. PubMed ID: 36210214
    [No Abstract]   [Full Text] [Related]  

  • 7. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line pembrolizumab therapy in a cisplatin-ineligible patient with plasmacytoid urothelial carcinoma: A case report.
    Hunter L; Moser J; Sturge C; Barraza G; Colonna S
    J Oncol Pharm Pract; 2020 Jan; 26(1):216-219. PubMed ID: 30832555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma.
    Achkar T; Parikh RA
    Urol Clin North Am; 2018 May; 45(2):257-266. PubMed ID: 29650141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
    Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
    Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guideline on urothelial carcinoma of the bladder].
    Bevers RF; Battermann JJ; Gietema JA; Hulsbergen-Van de Kaa CA; de Reijke TM; Feller N; Witjes JA; ;
    Ned Tijdschr Geneeskd; 2009; 153():A956. PubMed ID: 20051162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy for bladder cancer.
    Sonpavde G; Lerner SP
    Oncology (Williston Park); 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694. PubMed ID: 18247016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
    Meyer A; Ghandour R; Bergman A; Castaneda C; Wosnitzer M; Hruby G; Benson M; McKiernan J
    J Urol; 2014 Sep; 192(3):696-701. PubMed ID: 24657802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic chemotherapy for urothelial cancer.
    Sonpavde G; Hutson TE; Berry WR
    Clin Genitourin Cancer; 2006 Jun; 5(1):34-42. PubMed ID: 16859577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facing treatment of non-urothelial bladder cancers in the immunotherapy era.
    Grilo I; Rodrigues C; Soares A; Grande E
    Crit Rev Oncol Hematol; 2020 Sep; 153():103034. PubMed ID: 32622321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
    Turker P; Segersten U; Malmström PU; Hemdan T
    Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
    [No Abstract]   [Full Text] [Related]  

  • 20. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
    Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.